GlassScriptPhysician profile
Jessica M Greer
NPI 1881031631
$3,930.77
in general payments reported to CMS, 2019-2025
43 companies · $591 in 2025
The $591 reported for 2025 was more than what 84% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $557 · 2020: $247 · 2021: $709 · 2022: $703 · 2023: $633 · 2024: $491 · 2025: $591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,715.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $685.66 | 2019-2023 | |
| Sage Therapeutics, LLC | $244.89 | 2021-2025 | Zurzuvae |
| Daiichi Sankyo INC. | $228.68 | 2019-2023 | Injectafer |
| Astellas Pharma US INC | $201.57 | 2024-2025 | Veozah |
| Myovant Sciences INC. | $176.49 | 2021-2022 | |
| Coopersurgical, INC. | $168.73 | 2019-2025 | Paragard T 380a, Summit Doppler |
| Therapeuticsmd, INC. | $161.25 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $149.71 | 2019-2024 | |
| Exeltis, USA INC. | $146.72 | 2021-2025 | Slynd |
| Hologic Sales and Service, LLC | $142.61 | 2022-2024 | Thinprep 2000 Processor, Aptima, Affirm Prone Biopsy System |
| Sumitomo Pharma America, INC. | $134.22 | 2023-2025 | Myfembree |
| Pfizer INC. | $124.13 | 2020-2024 | |
| Mayne Pharma Commercial LLC | $111.30 | 2022-2025 | |
| Mylan Pharmaceuticals INC. | $97.19 | 2019-2022 | |
| Gynesonics, INC. | $91.11 | 2022 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $73.38 | 2024-2025 | Intrarosa, Femlyv |
| Organon LLC | $69.49 | 2022-2025 | Nexplanon |
| Agile Therapeutics, INC. | $69.44 | 2022-2024 | Twirla |
| Evofem Biosciences, INC. | $64.39 | 2021-2022 | |
| Novo Nordisk INC | $58.14 | 2024-2025 | Wegovy |
| Baxter Healthcare | $56.03 | 2022-2023 | Adept |
| Avion Pharmaceuticals | $54.80 | 2019-2023 | Balcoltra |
| Exact Sciences Corporation | $54.20 | 2023-2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $54.01 | 2023-2025 | Mounjaro, Zepbound, Emgality |
| Shield Therapeutics INC | $49.17 | 2023 | Accrufer |
| Meditrina | $46.70 | 2023-2025 | |
| Covidien LP | $42.26 | 2019 | |
| Becton, Dickinson and Company | $42.07 | 2021 | |
| Ethicon US, LLC | $41.02 | 2024 | Enseal |
| Merck Sharp & Dohme LLC | $35.45 | 2020-2021 | |
| Dexcom, INC. | $31.53 | 2025 | Dexcom G6 Transmitter |
| Vertical Pharmaceuticals, LLC | $30.50 | 2019 | |
| Amgen INC. | $29.66 | 2022 | |
| Karl Storz Endoscopy-America | $21.92 | 2024 | |
| Channel Medsystems, INC. | $20.35 | 2023 | |
| Boston Scientific Corporation | $20.03 | 2021 | |
| Duchesnay USA Incorporated | $17.45 | 2019 | |
| Supernus Pharmaceuticals, INC. | $17.40 | 2025 | Qelbree |
| Pacira Pharmaceuticals Incorporated | $15.58 | 2023 | Exparel |
| Glaxosmithkline, LLC. | $14.10 | 2022 | |
| Medicem INC. | $13.90 | 2021 | |
| Roche Diagnostics Corporation | $11.97 | 2019 | |
| Amag Pharmaceuticals, INC. | $11.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Greer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.